Hayashi Taichi
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba.
Nihon Rinsho. 2013 Jul;71(7):1227-31.
Golimumab is one of the TNF-inhibitors, having an efficacy and safety profile comparable to other TNF-inhibitors. In addition, golimumab is a fully human monoclonal antibody, has several unique features, such as neutralizing antibodies are difficult to generate. In clinical trials carried out in Japan, the efficacy and safety of administration of golimumab 100 mg every 4 weeks is shown, and golimumab blood concentration related to efficacy have been pointed out. From these, golimumab is considered a useful drug in every step of the treatment of rheumatoid arthritis. This section reviews the clinical trials of golimumab, and consider the useful use of golimumab.
戈利木单抗是肿瘤坏死因子抑制剂之一，其疗效和安全性与其他肿瘤坏死因子抑制剂相当。此外，戈利木单抗是一种全人单克隆抗体，具有几个独特的特性，例如难以产生中和抗体。在日本进行的临床试验中，显示了每4周给予100mg戈利木单抗的疗效和安全性，并且指出了与疗效相关的戈利木单抗血药浓度。由此可见，戈利木单抗在类风湿关节炎治疗的各个阶段都被认为是一种有用的药物。本节回顾了戈利木单抗的临床试验，并探讨了戈利木单抗的合理使用。
